ROSEN urges investors in Skye Bioscience to act before January 2026 deadline

The law firm Rosen Law Firm is sounding the alarm to anyone who purchased securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025: you may have the right to join a class‑action lawsuit — but only if you act before the critical deadline on January 16, 2026. According to Rosen, plaintiffs allege that Skye misled investors by overstating the prospects of its experimental drug nimacimab — claiming it was more effective, and that its clinical, regulatory, and commercial outlook was stronger than the facts supported. When this optimism failed to materialize, investors reportedly suffered financial harm. If you bought SKYE shares during the “Class Period,” you might be eligible to recover losses — without paying any upfront costs, thanks to a contingency‑fee arrangement. To participate (or to seek status as lead plaintiff), you must submit a form or contact Rosen by the January 16 cutoff. Rosen highlights its extensive track record in securities‑fraud litigation — including the largest ever securities class‑action settlement against a Chinese company, and more than US$438 million recovered for investors in 2019 alone. #SkyeBioscience #ClassAction #InvestorAlert #RosenLawFirm #SlimScan #GrowthStocks #CANSLIM